Development of less invasive surgical procedures for thoracic esophageal cancer.

In order to minimize the invasiveness of the operative procedure for thoracic esophageal cancer, several procedures have been introduced since January 1997. They included: (i) perioperative use of steroids; (ii) muscle-sparing thoracotomy without costectomy; (iii) preparation of the gastric tube with preservation of sufficient blood supply; (iv) reconstruction of the alimentary tract via posterior-mediastinal route; and (v) formation of anastomosis between the remaining esophagus and the gastric tube at a location between the gastroepiploic arteries of the gastric greater curvature. Twenty-one patients who did not receive preoperative chemoradiotherapy underwent the newly developed procedure, and were compared with those receiving the original procedure. Hospital mortality was zero, and postoperative systemic inflammatory response syndrome was suppressed. The mean postoperative hospital stay was 21.5 days, and the actuarial 3-year survival rate was 76.2%. From the comparison with those receiving the original procedure, it can be concluded that the newly developed procedures were effective in minimizing surgical invasiveness and were sufficiently curative in terms of cancer treatment.

[1]  T. Iwaya,et al.  Randomized Study of the Benefits of Preoperative Corticosteroid Administration on the Postoperative Morbidity and Cytokine Response in Patients Undergoing Surgery for Esophageal Cancer , 2002, Annals of surgery.

[2]  C. McConkey,et al.  Surgical workload and outcome after resection for carcinoma of the oesophagus and cardia , 2002, The British journal of surgery.

[3]  J. Siewert,et al.  Esophageal cancer: patient evaluation and pre-treatment staging. , 2001, Surgical oncology.

[4]  J. Wong,et al.  What Is Appropriate Treatment for Carcinoma of the Thoracic Esophagus? , 2001, World Journal of Surgery.

[5]  M. Arima,et al.  Clinical benefits of steroid therapy on surgical stress in patients with esophageal cancer. , 2000, Surgery.

[6]  T. Rice Superficial oesophageal carcinoma: is there a need for three-field lymphadenectomy? , 1999, The Lancet.

[7]  Y. Tabira,et al.  Indications for three-field dissection followed by esophagectomy for advanced carcinoma of the thoracic esophagus. , 1999, The Journal of thoracic and cardiovascular surgery.

[8]  Satoshi Suzuki,et al.  Outcomes of extended radical esophagectomy for thoracic esophageal cancer. , 1998, Journal of the American College of Surgeons.

[9]  N. Altorki,et al.  Occult cervical nodal metastasis in esophageal cancer: preliminary results of three-field lymphadenectomy. , 1997, The Journal of thoracic and cardiovascular surgery.

[10]  T. Nishihira,et al.  Association between elevated plasma granulocyte colony-stimulating factor and the degree of surgical stress in patients undergoing gastrointestinal surgery , 1995, Surgery Today.

[11]  Y. Kajiyama,et al.  Radical Lymph Node Dissection for Cancer of the Thoracic Esophagus , 1994, Annals of surgery.

[12]  F. Detterbeck,et al.  Vertical muscle-sparing thoracotomy. , 1994, The Annals of thoracic surgery.

[13]  H. Fujita,et al.  Mortality and morbidity rates, postoperative course, quality of life, and prognosis after extended radical lymphadenectomy for esophageal cancer. Comparison of three-field lymphadenectomy with two-field lymphadenectomy. , 1993 .

[14]  R. Ginsberg,et al.  Alternative (muscle-sparing) incisions in thoracic surgery. , 1993, The Annals of thoracic surgery.

[15]  E. Lesaffre,et al.  Surgical strategies in esophageal carcinoma with emphasis on radical lymphadenectomy. , 1992, Annals of surgery.

[16]  W. Knaus,et al.  Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. , 1992, Chest.

[17]  Y. Tachimori,et al.  Evaluation of neck lymph node dissection for thoracic esophageal carcinoma. , 1991, The Annals of thoracic surgery.

[18]  Woods Je,et al.  Cellular immunity after intravenous administration of methylprednisolone. , 1974 .

[19]  D. Browne Patent Ductus Arteriosus , 1952, Proceedings of the Royal Society of Medicine.

[20]  K. Isono,et al.  Results of a nationwide study on the three-field lymph node dissection of esophageal cancer. , 1991, Oncology.